{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:42:02Z","timestamp":1754145722827,"version":"3.41.2"},"reference-count":32,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"unspecified","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","award":["2023NSFSC1045"],"award-info":[{"award-number":["2023NSFSC1045"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202308510279"],"award-info":[{"award-number":["202308510279"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["72204039"],"award-info":[{"award-number":["72204039"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,6,20]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>The past decade has witnessed significant advancements in genome-targeted oncology drugs within the realm of precision medicine (PM). However, the cost-effectiveness of oncology PM in a highly populated, low- and middle-income country such as China remains uncertain, particularly due to the absence of systematic reviews conducted in Chinese that address this critical issue. This research protocol outlines a systematic review and meta-analysis aimed at evaluating the cost-effectiveness of genome-targeted anticancer drugs in China.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>We will perform a comprehensive search on both English-based and Chinese-specific databases, including MEDLINE (Ovid), Embase (Ovid), Chinese Biomedical Literature Database, China National Knowledge Infrastructure, VIP and Wan Fang. The search would be restricted to cost-effectiveness analysis of genome-targeted drugs approved by the National Medical Products Administration of China from 2002 to 2023. Health and economic outcomes will be extracted, and the biases of research will be assessed by the economic evaluations bias checklist. Based on the comparative efficiency research method, we will calculate and pool the net money benefit of genome-targeted oncology drugs relative to usual care using both the random-model and fixed-effect meta-analysis models. Next, meta-regression and jackknife sensitivity analysis will be carried out to identify sources of heterogeneity. In addition, subgroup analyses will be performed according to different cancer types and stages, patient demographics, drug classification and so forth.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>This study does not involve human or animal subjects, and thus, no ethical approval was required. The findings will be communicated via presentations, conference abstracts and scholarly articles intended for submission to peer-reviewed journals.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PROSPERO registration number<\/jats:title>\n                  <jats:p>CRD42024537386.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-093416","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T10:05:16Z","timestamp":1752746716000},"page":"e093416","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of precision medicine in oncology setting in China: protocol for a systematic review and meta-analysis"],"prefix":"10.1136","volume":"15","author":[{"given":"Qian","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5969-8085","authenticated-orcid":false,"given":"Dongni","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chengdu Fifth People\u2019s Hospital, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China"},{"name":"School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Li","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunlong","family":"Ou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8201-7145","authenticated-orcid":false,"given":"Wenjia","family":"Chen","sequence":"additional","affiliation":[{"name":"Saw Swee Hock School of Public Health, National University of Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"2025071703050849000_15.7.e093416.1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-057537","article-title":"Assessing the cost-effectiveness of precision medicine: protocol for a systematic review and meta-analysis","volume":"12","author":"Chen","year":"2022","journal-title":"BMJ Open"},{"key":"2025071703050849000_15.7.e093416.2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jamaoncol.2018.1660","article-title":"Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology","volume":"4","author":"Marquart","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025071703050849000_15.7.e093416.3","unstructured":"Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease\/committee on a framework for developing a new taxonomy of disease, board on life sciences, division on earth and life sciences, national research council of the national academies. Washington, DC National Academies Press; 2011."},{"key":"2025071703050849000_15.7.e093416.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30698-8"},{"key":"2025071703050849000_15.7.e093416.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1500523"},{"key":"2025071703050849000_15.7.e093416.6","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/joim.13698","article-title":"Implementation of precision medicine in healthcare-A European perspective","volume":"294","author":"Stenzinger","year":"2023","journal-title":"J Intern Med"},{"key":"2025071703050849000_15.7.e093416.7","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.currproblcancer.2017.02.003","article-title":"The current status and problems confronted in delivering precision medicine in Japan and Europe","volume":"41","author":"Bando","year":"2017","journal-title":"Curr Probl Cancer"},{"key":"2025071703050849000_15.7.e093416.8","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41588-022-01274-x","article-title":"The Singapore National Precision Medicine Strategy","volume":"55","author":"Wong","year":"2023","journal-title":"Nat Genet"},{"key":"2025071703050849000_15.7.e093416.9","first-page":"170","article-title":"Thinking on the Standardized Training and Teaching Mode of Oncology Residents in the Era of \u2018Precision Medicine","volume":"7","author":"Qin","year":"2024","journal-title":"China Continuing Medical"},{"key":"2025071703050849000_15.7.e093416.10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature New Biol"},{"key":"2025071703050849000_15.7.e093416.11","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.apsb.2014.01.002","article-title":"Research and development in drug innovation: reflections from the 2013 bioeconomy conference in China, lessons learned and future perspectives","volume":"4","author":"Liu","year":"2014","journal-title":"Acta Pharm Sin B"},{"key":"2025071703050849000_15.7.e093416.12","unstructured":"National Research Council (US) Committee on A Framework for Developing a New Taxonomy of Disease . Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. Washington (DC) National Academies Press (US); 2011."},{"key":"2025071703050849000_15.7.e093416.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00195-4"},{"key":"2025071703050849000_15.7.e093416.14","first-page":"1036","article-title":"Current Situation and Implications of Novel Antitumer Drugs in China","volume":"06","author":"Sun","year":"2022","journal-title":"Medical Journal of Peking Union Medical College Hospital"},{"key":"2025071703050849000_15.7.e093416.15","first-page":"128","article-title":"Research progress of anti-tumor-targeted drugs","volume":"21","author":"Li","year":"2021","journal-title":"China Pharmaceuticals"},{"key":"2025071703050849000_15.7.e093416.16","first-page":"1854","article-title":"Cost-utility Analysis of atezolizumab in the second-line treatment of metastatic non-small cell lung cancer","volume":"41","author":"Zhang","year":"2022","journal-title":"Herald of Medicine"},{"key":"2025071703050849000_15.7.e093416.17","first-page":"1885","article-title":"Systematic Analysis of Economic Evaluation of Listed PD-1\/PD-L1 Inhibitors in China","volume":"15","author":"Ma","year":"2021","journal-title":"China Pharmacy"},{"key":"2025071703050849000_15.7.e093416.18","doi-asserted-by":"crossref","first-page":"590","DOI":"10.5246\/jcps.2021.07.047","article-title":"The impact of the provincial reimbursement scheme on the use of targeted anticancer medications in Zhejiang, China: a controlled interrupted time-series analysis","volume":"30","year":"2021","journal-title":"J Chin Pharm Sci"},{"key":"2025071703050849000_15.7.e093416.19","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.35123","article-title":"Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020","volume":"4","author":"Haslam","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025071703050849000_15.7.e093416.20","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"2025071703050849000_15.7.e093416.21","doi-asserted-by":"crossref","DOI":"10.1007\/s40273-020-00950-2","article-title":"Correction to: Calculating and Interpreting ICERs and Net Benefit","volume":"38","author":"Paulden","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"2025071703050849000_15.7.e093416.22","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.jval.2022.01.006","article-title":"The Net Benefit of Personalized Medicine: A Systematic Literature Review and Regression Analysis","volume":"25","author":"Vellekoop","year":"2022","journal-title":"Value Health"},{"key":"2025071703050849000_15.7.e093416.23","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.2015.1103185"},{"key":"2025071703050849000_15.7.e093416.24","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2016.1246961"},{"key":"2025071703050849000_15.7.e093416.25","doi-asserted-by":"crossref","first-page":"1151504","DOI":"10.3389\/fpubh.2023.1151504","article-title":"Mapping the value for money of precision medicine: a systematic literature review and meta-analysis","volume":"11","author":"Chen","year":"2023","journal-title":"Front Public Health"},{"key":"2025071703050849000_15.7.e093416.26","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-14-139","article-title":"Comparative efficiency research (COMER): meta-analysis of cost-effectiveness studies","volume":"14","author":"Crespo","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2025071703050849000_15.7.e093416.27","unstructured":"National Bureau of Statistics . Statistical bulletin of the people\u2019s Republic of China on national economic and social development in 2023. People\u2019s Daily; 2024."},{"key":"2025071703050849000_15.7.e093416.28","unstructured":"Ding L . Health economic comparison and prediction of mammography and ultrasound-based breastcancer screening in Chines. Tianjin Medical University; 2018."},{"key":"2025071703050849000_15.7.e093416.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(97)00049-8"},{"key":"2025071703050849000_15.7.e093416.30","doi-asserted-by":"crossref","DOI":"10.1177\/1073274820902271","article-title":"Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer","volume":"27","author":"Han","year":"2020","journal-title":"Cancer Control"},{"key":"2025071703050849000_15.7.e093416.31","unstructured":"West SL , Gartlehner G , Mansfield AJ , et al . Table 7, summary of common statistical approaches to test for heterogeneity. 2021. Available: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK53317\/table\/ch3.t2\/"},{"key":"2025071703050849000_15.7.e093416.32","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1090361","article-title":"Cost-effectiveness of janus kinase inhibitors for rheumatoid arthritis: A systematic review and meta-analysis of cost-utility studies","volume":"13","author":"Kumar","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-093416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T10:05:20Z","timestamp":1752746720000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-093416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,17]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjopen-2024-093416"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-093416","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}